ENDOTHELIN-1 AS A RISK FACTOR IN RETINAL VEIN OCCLUSION.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
pubmed:
4
12
2021
medline:
19
4
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Retinal vein occlusion (RVO) risk factors largely coincide with cardiovascular risk factors. Endothelin-1 (ET-1), the most potent vasoconstrictor with proinflammatory properties, is a known cardiovascular risk factor. In this study, we explore the role of serum ET-1 as a potential risk factor for RVO. Endothelin-1 serum levels were measured in patients with RVO and control subjects. Samples were measured using the sandwich enzyme-linked immunosorbent assay for the quantitative determination of human big endothelin-1 (Biomedica Group, Austria). The study consisted of 147 RVO patients and 150 control subjects. Median serum ET-1 was significantly higher in RVO patients (0.26 pmol/L; range, 0.19-0.37 pmol/L) compared with control subjects (0.10 pmol/L; range, 0.05-0.22 pmol/L) (P < 0.0001) independent of the occlusion site. The difference remained significant after adjusting for arterial hypertension, diabetes mellitus, history of stroke, history of myocardial infarction, history of venous thromboembolism, glomerular filtration rate, and c-reactive protein. In conclusion, our results suggest that ET-1 is a potential risk factor for all types of RVO.
Identifiants
pubmed: 34861658
doi: 10.1097/IAE.0000000000003374
pii: 00006982-202204000-00017
doi:
Substances chimiques
Endothelin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
738-743Références
Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health 2019;9:010427.
O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008;126:692–699.
Kowalczyk A, Kleniewska P, Kolodziejczyk M, et al. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz) 2015;63:41–52.
Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev 2016;68:357–418.
Antonopoulos A, Kyriacou C, Kazianis G. Significance of endothelin-1 in myocardial infarction. Hellenic J Cardiol 2007;48:161–164.
Koyama Y, Hayashi M, Nagae R, et al. Endothelin-1 increases the expression of VEGF-R1/Flt-1 receptors in rat cultured astrocytes through ETB receptors. J Neurochem 2014;130:759–769.
Anggrahini DW, Emoto N, Nakayama K, et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc Res 2009;82:143–151.
Kida T. Mystery of retinal vein occlusion: vasoactivity of the vein and possible involvement of endothelin-1. Biomed Res Int 2017;2017:4816527.
Chen YL, Ren Y, Xu W, et al. Constriction of retinal venules to endothelin-1: obligatory roles of ETA receptors, extracellular calcium entry, and rho kinase. Invest Ophthalmol Vis Sci 2018;59:5167–5175.
Polak K, Luksch A, Frank B, et al. Regulation of human retinal blood flow by endothelin-1. Exp Eye Res 2003;76:633–640.
Iannaccone A, Letizia C, Pazzaglia S, et al. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol 1998;82:498–503.
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995;102:1434–1444.
Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986;104:34–41.
Risk factors for branch retinal vein occlusion. The eye disease case-control study group. Am J Ophthalmol 1993;116:286–296.
Sperduto RD, Hiller R, Chew E, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 1998;105:765–771.
Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993;37:393–417.
Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999;106:2054–2062.
Zhao J, Sastry SM, Sperduto RD, et al. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993;100:423–428.
Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004;111:133–141.
Chou KT, Huang CC, Tsai DC, et al. Sleep apnea and risk of retinal vein occlusion: a nationwide population-based study of Taiwanese. Am J Ophthalmol 2012;154:200–205.e1.
Glacet-Bernard A, les Jardins GL, Lasry S, et al. Obstructive sleep apnea among patients with retinal vein occlusion. Arch Ophthalmol 2010;128:1533–1538.
Lahey JM, Tunç M, Kearney J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002;109:126–131.
Kida T, Flammer J, Oku H, et al. Suppressed endothelin-1 by anti-VEGF therapy is important for patients with BRVO-related macular edema to improve their vision. EPMA J 2016;7:18.
Haufschild T, Prünte C, Messerli J, Flammer J. Increased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monbl Augenheilkd 2004;221:357–359.
Perez AL, Grodin JL, Wu Y, et al. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. Eur J Heart Fail 2016;18:290–297.
Gohar EY, Pollock DM. Sex-specific contributions of endothelin to hypertension. Curr Hypertens Rep 2018;20:58.
Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997–1001.